Nuvectis Pharma, Inc.
Clinical trials sponsored by Nuvectis Pharma, Inc., explained in plain language.
-
New cancer drug enters first human tests
Disease control Recruiting nowThis early-phase study tests a new drug called NXP900 in about 140 adults with advanced solid tumors (like lung, kidney, or mesothelioma) that have not responded to standard treatments. The goal is to find a safe dose and check for side effects, while also looking for signs that …
Phase: PHASE1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Jun 17, 2026 03:08 UTC
-
New hope for lung cancer patients when standard therapy fails
Disease control Recruiting nowThis early-stage study tests a new drug called NXP900 combined with the standard drug osimertinib in 18 adults with advanced EGFR-mutant lung cancer that has gotten worse on osimertinib alone. The goal is to see if the combination is safe and can shrink tumors or slow the cancer'…
Phase: PHASE1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Jun 05, 2026 12:06 UTC